Seven patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2041
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2043.20262031203620412043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
13 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2042 · High confidence
Also notable
Ends May 2041 · High confidence
Also notable
Ends Apr 2043 · High confidence
Inhibitors of LRRK2 Kinase
US 11,578,061
The earliest of the three still in force, granted 2023 and renewed since. Its term ends first, in 2042.
Inhibitors of NEK7 Kinase
US 11,713,321
A family of 6 related applications built on the 2023 grant. Protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
NEK7 Inhibitors
US 12,709,616
Granted 2026. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 1, 2027The maintenance fee for Inhibitors of NEK7 Kinase (US 11,713,321) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Inhibitors of LRRK2 Kinase (US 11,866,423) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Inhibitors of LRRK2 Kinase | 3 in force | to Mar 2042 |
| Inhibitors of NEK7 Kinase | 3 in force | to May 2041 |
| NEK7 Inhibitors | 1 in force | to Apr 2043 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,161,852 | Inhibitors of NEK7 Kinase In force · High confidence | In force | High confidence | |
| US 11,713,321 | Inhibitors of NEK7 Kinase In force · High confidence | In force | High confidence | |
| US 12,091,413 | Inhibitors of NEK7 Kinase In force · Medium confidence | In force | Medium confidence | |
| US 11,578,061 | Inhibitors of LRRK2 Kinase In force · High confidence | In force | High confidence | |
| US 11,866,423 | Inhibitors of LRRK2 Kinase In force · High confidence | In force | High confidence | |
| US 12,428,404 | Inhibitors of LRRK2 Kinase In force · High confidence | In force | High confidence | |
| US 12,709,616 | NEK7 Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 13 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.